Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusiomal 5-Fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study

R. L. Martino, T. R. Fleming, L. M. Morrell, Bach Ardalan, Stephen P Richman, J. S. Macdonald

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

N-(phosphonacetyl)-disodium L-aspartic acid (PALA) demonstrates a synergistic antitumor effect when combined with 5-Fluorouracil (5-FU)in in vitro studies. In a Phase II trial, 23 eligible patients with unresectable or metastatic adenocarcinoma of the stomach-were treated with weekly i.v. bolus PALA (250 mg/M2) followed 24 hours later by a 24-hour infusion of 5-FU (2600 mg/M2) for an initial period of 8 weeks. No objective responses were noted. PALA and 5-FU is inactive against gastric adenocarcinoma at the doses and schedule used in this trial.

Original languageEnglish
Pages (from-to)419-421
Number of pages3
JournalInvestigational New Drugs
Volume14
Issue number4
StatePublished - Dec 1 1996
Externally publishedYes

Fingerprint

Aspartic Acid
Fluorouracil
Stomach
Adenocarcinoma
Appointments and Schedules

Keywords

  • 5-Fluorouracil
  • Advanced gastric cancer
  • PALA
  • Phase II study

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

@article{068f99dbb29e4829952623e7c2522a8f,
title = "Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusiomal 5-Fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study",
abstract = "N-(phosphonacetyl)-disodium L-aspartic acid (PALA) demonstrates a synergistic antitumor effect when combined with 5-Fluorouracil (5-FU)in in vitro studies. In a Phase II trial, 23 eligible patients with unresectable or metastatic adenocarcinoma of the stomach-were treated with weekly i.v. bolus PALA (250 mg/M2) followed 24 hours later by a 24-hour infusion of 5-FU (2600 mg/M2) for an initial period of 8 weeks. No objective responses were noted. PALA and 5-FU is inactive against gastric adenocarcinoma at the doses and schedule used in this trial.",
keywords = "5-Fluorouracil, Advanced gastric cancer, PALA, Phase II study",
author = "Martino, {R. L.} and Fleming, {T. R.} and Morrell, {L. M.} and Bach Ardalan and Richman, {Stephen P} and Macdonald, {J. S.}",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "14",
pages = "419--421",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusiomal 5-Fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study

AU - Martino, R. L.

AU - Fleming, T. R.

AU - Morrell, L. M.

AU - Ardalan, Bach

AU - Richman, Stephen P

AU - Macdonald, J. S.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - N-(phosphonacetyl)-disodium L-aspartic acid (PALA) demonstrates a synergistic antitumor effect when combined with 5-Fluorouracil (5-FU)in in vitro studies. In a Phase II trial, 23 eligible patients with unresectable or metastatic adenocarcinoma of the stomach-were treated with weekly i.v. bolus PALA (250 mg/M2) followed 24 hours later by a 24-hour infusion of 5-FU (2600 mg/M2) for an initial period of 8 weeks. No objective responses were noted. PALA and 5-FU is inactive against gastric adenocarcinoma at the doses and schedule used in this trial.

AB - N-(phosphonacetyl)-disodium L-aspartic acid (PALA) demonstrates a synergistic antitumor effect when combined with 5-Fluorouracil (5-FU)in in vitro studies. In a Phase II trial, 23 eligible patients with unresectable or metastatic adenocarcinoma of the stomach-were treated with weekly i.v. bolus PALA (250 mg/M2) followed 24 hours later by a 24-hour infusion of 5-FU (2600 mg/M2) for an initial period of 8 weeks. No objective responses were noted. PALA and 5-FU is inactive against gastric adenocarcinoma at the doses and schedule used in this trial.

KW - 5-Fluorouracil

KW - Advanced gastric cancer

KW - PALA

KW - Phase II study

UR - http://www.scopus.com/inward/record.url?scp=0030481427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030481427&partnerID=8YFLogxK

M3 - Article

C2 - 9157080

AN - SCOPUS:0030481427

VL - 14

SP - 419

EP - 421

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -